Clinical Trials Logo

Clinical Trial Summary

Pulpotomy of vital primary molars is indicated when caries removal results in pulp exposure. Treatment approaches consist of devitalization using formocresol, preservation using ferric sulfate and regeneration of the remaining pulp tissue using mineral trioxide aggregate and recently Biodentine have been utilized. The ideal pulpotomy medicament would be biocompatible and bactericidal, in addition, to promoting the healing of the root pulp and be compatible with the physiological process of root resorption. Searching for more pulpotomy agents, Collagen, a protein that's present abundantly in humans, is an important component of connective tissues and performs multiple functions including wound healing. Enamel and dentin contain Collagen as one of the components in their organic ground matrix. Collagen has been used widely in dentistry in periodontal and implant therapy as scaffold for preventing the migration of epithelial cells and encouraging wound repopulation by cells with high regenerative potential. The Collagen available for dental implication is already sterilized and also reinforced with antibiotic particles to efficiently aid in regeneration and repair without any contamination. The collagen particles


Clinical Trial Description

Pulpotomy is considered the gold standard procedure for treating cariously exposed pulps in asymptomatic primary teeth. Which is based on the healing ability of the radicular pulp tissue following amputation of the infected coronal pulp. Mineral trioxide aggregate (MTA) has been recommended as the gold standard for vital pulp therapy; however, it has some disadvantages, such as long setting time, poor handling properties, high cost, and the potential for tooth discoloration. Biodentine (Septodont, Saint-Maur-des-Fossés, France), one of the new-generation, bioactive endodontic cements, has been claimed to have improved properties over MTA. Biodentine presents high biocompatibility with the dental pulp, it has high antibacterial effects and antifungal activity, has a shorter setting time than MTA as a result of the calcium chloride in the liquid component of Biodentine. It also has higher flexural strength, compressive strength and modulus of elasticity than MTA. Consequently, Biodentine can be used as a pulp dressing as well as a base material. Quest is on for newer pulpal medicaments that are biocompatible and capable of healing the dental pulp by producing reparative dentin and/or dentinal bridge in response to various stimuli and surgical exposure. Collagen has a proven rate of success in the field of dentistry as guided tissue regeneration, root conditioning, hemostatic, and wound dressing agent. It has inherent properties like low immune response and toxicity, ability to promote cellular growth and attachment, homeostasis, and added advantage of antibiotic incorporation. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05479877
Study type Interventional
Source Cairo University
Contact Nihal Bayoumi, Msc
Phone +201227610630
Email nihal.mostafa@dentistry.cu.edu.eg
Status Not yet recruiting
Phase Early Phase 1
Start date September 2022
Completion date October 2023

See also
  Status Clinical Trial Phase
Not yet recruiting NCT06378814 - Outcome of Selective & Nonselective Caries Removal in Permanent Teeth N/A
Active, not recruiting NCT05937100 - New Vital Pulpotomy Medications in Primary Molars N/A
Recruiting NCT05279820 - Comparative Study of the Outcome of Partial and Full Pulpotomy in Irreversible Pulpits N/A
Completed NCT03838094 - Evaluation of MTA Versus Biodentine as Pulpotomy Agents in Immature First Permanent Molars Phase 1/Phase 2